-
5-HT3 Antagonists Inhibit Renal OCT2 and MATE1: In Vitro Ins
2026-06-04
This study systematically examines how widely used 5-HT3 receptor antagonists, including palonosetron hydrochloride, inhibit the renal transporters OCT2 and MATE1 in vitro. The findings clarify the relative inhibitory potencies among antiemetic drugs and highlight implications for drug-drug interactions that may impact chemotherapy and renal pharmacology research.
-
Alosetron (A3157): Optimizing 5-HT3 Antagonism in GI Cell As
2026-06-04
This article provides a scenario-driven, research-focused guide for using Alosetron (SKU A3157) in cell viability and cytotoxicity assays involving gastrointestinal models. Emphasizing reproducibility, serotonin receptor pharmacology, and practical workflow optimization, it bridges recent advances in epithelial signaling with hands-on laboratory best practices. APExBIO’s Alosetron is highlighted for its purity, solubility, and reliability.
-
Methylprednisolone: Applied Workflows for Anti-Inflammatory
2026-06-03
Unlock the full experimental potential of methylprednisolone—a synthetic glucocorticoid receptor agonist—with precise in vitro and in vivo protocols. Discover troubleshooting tips, advanced use-cases, and key workflow enhancements drawn from cutting-edge osteonecrosis research.
-
Dihydroartemisinin: Translating Mechanistic Insight Into Res
2026-06-03
This article offers a strategic and mechanistic deep dive into the application of dihydroartemisinin, focusing on its dual role as an antimalarial and mTOR pathway inhibitor. It bridges biological rationale with practical guidance for translational researchers, referencing recent antiplasmodial studies and comparative analyses to position APExBIO’s dihydroartemisinin as a next-generation research tool. The article uniquely integrates protocol recommendations, cross-domain perspectives, and a forward-looking outlook rooted in evidence.
-
Prednisolone in Advanced Glucocorticoid Signaling and ERAD R
2026-06-02
Discover how Prednisolone, a synthetic glucocorticoid, empowers next-generation research on glucocorticoid signaling and ERAD-mediated protein degradation. This in-depth analysis reveals unique experimental strategies and practical assay advantages.
-
Cimetidine: Optimizing H2 Antagonist Use in BBB & GI Models
2026-06-02
Cimetidine’s unique partial H2 receptor activity and robust solubility empower high-fidelity blood-brain barrier and gastrointestinal cancer research. This guide translates current experimental breakthroughs and troubleshooting strategies into actionable workflows using APExBIO’s rigorously purified Cimetidine.
-
Dual-Reporter mRNA Innovation: Unlocking Advanced mRNA Track
2026-06-01
Explore the molecular advantages of EZ Cap Cy5 Firefly Luciferase mRNA, a 5-moUTP modified mRNA enabling real-time dual-mode imaging and efficient delivery. This article reveals scientific insights and practical assay advances overlooked by existing reviews.
-
Hijacking ERAD: ERADECs Enable Targeted Degradation of TM Pr
2026-06-01
Song et al. introduce ERAD-engaging chimeras (ERADECs), a new class of small-molecule tools that exploit the ER-associated degradation (ERAD) pathway for selective, efficient degradation of transmembrane proteins such as PD-L1. This innovation overcomes longstanding barriers in targeted protein degradation, with implications for drug discovery and translational research in cancer and beyond.
-
Sulfo-NHS-Biotin: Precision Cell Surface Protein Labeling Un
2026-05-31
Sulfo-NHS-Biotin empowers researchers with water-soluble, amine-specific biotinylation—ideal for rapid, selective cell surface protein labeling. Discover robust, stepwise protocols, troubleshooting strategies, and how recent single-cell innovations translate to advanced protein interaction assays.
-
Cimetidine in BBB and Cancer Research: Protocols and Pitfall
2026-05-30
Cimetidine’s unique profile as a histamine-2 receptor antagonist enables advanced modeling of gastrointestinal cancer and blood-brain barrier (BBB) permeability. This guide translates recent breakthroughs—including high-throughput BBB models—into actionable workflows and troubleshooting insights for translational scientists.
-
Homoharringtonine: Cytotoxic Alkaloid for Cancer and Antivir
2026-05-29
Homoharringtonine is a cytotoxic alkaloid that inhibits protein synthesis via eukaryotic 80S ribosome binding. It demonstrates potent G1 phase arrest in leukemic cells and rapid SARS-CoV-2 clearance in preclinical and clinical studies. This compound is a validated research tool in both cancer biology and antiviral workflows.
-
U 46619: Strategic Insights for Translational Platelet and R
2026-05-29
This thought-leadership article from APExBIO provides translational researchers with an advanced roadmap for leveraging U 46619 (11,9 epoxymethano-prostaglandin H2) in dissecting platelet activation, vascular tone, and renal pathophysiology. We blend mechanistic detail, experimental best practices, and cross-study integration—bridging cardiovascular and renal research frontiers, contextualizing recent findings in ischemia-reperfusion injury, and offering actionable protocol guidance.
-
Triamcinolone Protocols: Technical Guidance for Research Use
2026-05-28
Triamcinolone is a synthetic glucocorticoid agonist suited for in vitro studies of glucocorticoid signaling, anti-inflammatory research, and immunosuppression workflows. This compound is not appropriate for diagnostic or medical use, and requires careful attention to solubility and storage parameters for reliable experimental results.
-
(S)-(+)-Ibuprofen: COX Inhibitor Workflows and Optimization
2026-05-28
(S)-(+)-Ibuprofen offers precise, reproducible COX inhibition for inflammation and pain research, combining high selectivity with robust tolerability. This guide translates fresh synthesis advances and experimental best practices into actionable workflows, troubleshooting, and comparative context for advanced nonsteroidal anti-inflammatory drug research.
-
DOT1L Inhibition Enhances Immunomodulatory Drug Efficacy in
2026-05-27
This study demonstrates that DOT1L inhibition reprograms innate immunity in multiple myeloma (MM), leading to stronger responses to immunomodulatory drugs such as lenalidomide. The findings clarify mechanistic links between DOT1L, interferon signaling, and anti-myeloma activity, highlighting new avenues for epigenetic-based combination therapies.